A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40.
A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40.
复制标题
DOI：
10.1186/s13045-015-0131-7
复制
发表时间：
2015-04-14
影响因子：
28.5
通讯作者：
Palucka AK
中科院分区：
文献类型：
--
作者：
Chen J;Zurawski G;Zurawski S;Wang Z;Akagawa K;Oh S;Hideki U;Fay J;Banchereau J;Song W;Palucka AK
套细胞淋巴瘤(MCL)是B细胞性非霍奇金淋巴瘤的一种独特的临床病理亚型，预后较差。需要以增强抗肿瘤免疫为基础的新的治疗方法。MCL与细胞周期蛋白D1的过度表达有关，因此使该分子成为免疫治疗的一个有趣的靶点。我们在这里展示了一种新的策略，用于开发携带Cyclin D1癌症抗原的重组疫苗，该疫苗可以通过CD40靶向树突状细胞(DC)。健康人和MCL患者有广泛的Cyclin D1特异性的CD4+和CD8+T细胞。细胞周期蛋白D1特异性T细胞分泌干扰素-γ。负载完整肿瘤细胞或部分多肽的DC可诱导细胞周期蛋白D1特异性CD8+T细胞杀伤MCL肿瘤细胞。我们研制了一种基于抗CD40单抗将细胞周期蛋白D1抗原靶向人树突状细胞的重组疫苗。以抗CD40-细胞周期蛋白D1融合蛋白体外靶向人单核细胞来源的树突状细胞，扩增了广泛的细胞周期蛋白D1特异性的CD4+和CD8+T细胞。本研究表明细胞周期蛋白D1是一种良好的免疫治疗靶点，靶向DC为套细胞淋巴瘤疫苗提供了一种新的策略。本文的在线版本(doi：10.1186/s13045-015-0131-7)包含补充材料，授权用户可以使用。
Mantle cell lymphoma (MCL) is a distinct clinical pathologic subtype of B cell non-Hodgkin’s lymphoma often associated with poor prognosis. New therapeutic approaches based on boosting anti-tumor immunity are needed. MCL is associated with overexpression of cyclin D1 thus rendering this molecule an interesting target for immunotherapy. We show here a novel strategy for the development of recombinant vaccines carrying cyclin D1 cancer antigens that can be targeted to dendritic cells (DCs) via CD40. Healthy individuals and MCL patients have a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. Cyclin D1-specific T cells secrete IFN-γ. DCs loaded with whole tumor cells or with selected peptides can elicit cyclin D1-specific CD8+ T cells that kill MCL tumor cells. We developed a recombinant vaccine based on targeting cyclin D1 antigen to human DCs via an anti-CD40 mAb. Targeting monocyte-derived human DCs in vitro with anti-CD40-cyclin D1 fusion protein expanded a broad repertoire of cyclin D1-specific CD4+ and CD8+ T cells. This study demonstrated that cyclin D1 represents a good target for immunotherapy and targeting cyclin D1 to DCs provides a new strategy for mantle cell lymphoma vaccine. The online version of this article (doi:10.1186/s13045-015-0131-7) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
3.7
作者：
Dao T;Korontsvit T;Zakhaleva V;Haro K;Packin J;Scheinberg DA
通讯作者：
Scheinberg DA
DOI：
10.1038/jid.2009.343
发表时间：
2010-03
期刊：
The Journal of investigative dermatology
影响因子：
--
作者：
通讯作者：
--
影响因子：
4.5
作者：
FAN, JQ;HALL, P
通讯作者：
HALL, P
影响因子：
15.3
作者：
Bonifaz, L;Bonnyay, D;Mahnke, K;Rivera, M;Nussenzweig, MC;Steinman, RM
通讯作者：
Steinman, RM
DOI：
10.1084/jem.194.6.769
发表时间：
2001-09-17
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Hawiger D;Inaba K;Dorsett Y;Guo M;Mahnke K;Rivera M;Ravetch JV;Steinman RM;Nussenzweig MC
通讯作者：
Nussenzweig MC